Astellas Pharma (ALPMY) Short Interest Ratio & Short Volume → is this a buy and hold stock? (From Tips4Traders) (Ad) Free ALPMY Stock Alerts $9.74 +0.12 (+1.25%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Astellas Pharma Short Interest DataCurrent Short Volume83,900 sharesPrevious Short Volume69,800 sharesChange Vs. Previous Month+20.20%Dollar Volume Sold Short$801,245.00Short Interest Ratio / Days to Cover0.1Last Record DateApril 30, 2024Outstanding Shares1,809,660,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume444,655 sharesAverage Trading Volume415,759 sharesToday's Volume Vs. Average107% Short Selling Astellas Pharma ? Sign up to receive the latest short interest report for Astellas Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatALPMY Short Interest Over TimeALPMY Days to Cover Over TimeALPMY Percentage of Float Shorted Over Time Ad Porter & CompanyAmerica’s worst nightmare?What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.Click here to watch this bombshell exposé now. Astellas Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202483,900 shares $801,245.00 +20.2%N/A0.1 $9.55 4/15/202469,800 shares $647,150.70 -59.4%N/A0.1 $9.27 3/31/2024171,800 shares $1.85 million +53.1%N/A0.3 $10.75 3/15/2024112,200 shares $1.21 million +51.6%N/A0.2 $10.83 2/29/202474,000 shares $808,820.00 +9.1%N/A0.2 $10.93 2/15/202467,800 shares $749,190.00 -19.7%N/A0.1 $11.05 Get the Latest News and Ratings for ALPMY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/202468,200 shares $823,856.00 -57.1%N/A0.2 $12.08 12/31/2023159,100 shares $1.89 million +305.9%N/A0.3 $11.90 12/15/202339,200 shares $445,312.00 -14.6%N/A0 $11.36 11/30/202345,900 shares $558,144.00 -7.8%N/A0.1 $12.16 11/15/202349,800 shares $579,921.00 +3.8%N/A0.1 $11.65 10/31/202348,000 shares $609,120.00 +1,197.3%N/A0.1 $12.69 10/15/20233,700 shares $48,248.00 -27.5%N/A0 $13.04 9/30/20235,100 shares $70,635.00 -54.1%N/A0 $13.85 9/15/202311,100 shares $165,501.00 -74.7%N/A0 $14.91 8/31/202343,900 shares $664,646.00 -43.9%N/A0.2 $15.14 8/15/202378,200 shares $1.18 million -38.0%N/A0.3 $15.13 7/31/2023126,200 shares $1.85 million +94.8%N/A0.3 $14.63 7/15/202364,800 shares $933,120.00 +9,157.1%N/A0.2 $14.40 6/30/2023700 shares $10,409.00 -98.3%N/A0 $14.87 6/15/202340,900 shares $659,308.00 -32.2%N/A0.5 $16.12 5/31/202360,300 shares $950,931.00 +61.2%N/A0.3 $15.77 5/15/202337,400 shares $599,522.00 +77.3%N/A0.4 $16.03 4/30/202321,100 shares $316,922.00 +64.8%N/A0.3 $15.02 4/15/202312,800 shares $189,568.00 -60.7%N/A0.1 $14.81 3/31/202332,600 shares $462,757.00 -26.4%N/A0.2 $14.20 3/15/202344,300 shares $610,011.00 -15.8%N/A0.2 $13.77 2/28/202352,600 shares $736,400.00 +310.9%N/A0.2 $14.00 2/15/202312,800 shares $183,936.00 +75.3%N/A0.1 $14.37 1/31/20237,300 shares $107,164.00 -73.7%N/A0 $14.68 1/15/202327,700 shares $404,974.00 -43.7%N/A0.2 $14.62 12/30/202249,200 shares $745,872.00 +278.5%N/A0.5 $15.16 12/15/202213,000 shares $202,410.00 -75.8%N/A0.2 $15.57 11/30/202253,600 shares $828,656.00 -48.9%N/A0.5 $15.46 11/15/2022104,900 shares $1.58 million +88.3%N/A0.4 $15.07 10/31/202255,700 shares $772,002.00 -50.2%N/A0.2 $13.86 10/15/2022111,900 shares $1.49 million +5.3%N/A0.3 $13.33 9/30/2022106,300 shares $1.42 million +544.2%N/A0.2 $13.33 9/15/202216,500 shares $227,205.00 No ChangeN/A0 $13.77 8/15/20222,000 shares $30,600.00 -95.6%N/A0 $15.30Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (Ad)Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. ALPMY Short Interest - Frequently Asked Questions What is Astellas Pharma's current short interest? Short interest is the volume of Astellas Pharma shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 83,900 shares of ALPMY short. Learn More on Astellas Pharma's current short interest. Is Astellas Pharma's short interest increasing or decreasing? Astellas Pharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 83,900 shares, an increase of 20.2% from the previous total of 69,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Astellas Pharma's short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Astellas Pharma: Alnylam Pharmaceuticals, Inc. (2.08%), Teva Pharmaceutical Industries Limited (1.09%), Genmab A/S (0.42%), BeiGene, Ltd. (1.93%), BioMarin Pharmaceutical Inc. (2.06%), Viatris Inc. (3.84%), Merck KGaA (0.53%), Sarepta Therapeutics, Inc. (6.02%), United Therapeutics Co. (9.42%), Dr. Reddy's Laboratories Limited (0.52%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Astellas Pharma stock? Short selling ALPMY is an investing strategy that aims to generate trading profit from Astellas Pharma as its price is falling. ALPMY shares are trading up $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Astellas Pharma? A short squeeze for Astellas Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALPMY, which in turn drives the price of the stock up even further. How often is Astellas Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALPMY, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: ALNY Short Interest TEVA Short Interest GMAB Short Interest BGNE Short Interest BMRN Short Interest VTRS Short Interest MKGAF Short Interest SRPT Short Interest UTHR Short Interest RDY Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ALPMY) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHow to Make 100X on the AI BoomInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishing